Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Nov;64(5):968–970. doi: 10.1038/bjc.1991.438

A prospective randomised trial of radiation with or without oral and intravesical misonidazole for bladder cancer.

R P Abratt 1, P Craighead 1, V B Reddi 1, L A Sarembock 1
PMCID: PMC1977474  PMID: 1931628

Abstract

Patients with T2 grade 3 and T3 bladder cancer were randomised to be treated with radiation alone (NO MISO) or with radiation and misonidazole (PLUS MISO). Patients in both groups initially received 40 Gy in 2 Gy fractions (5/week). Patients in the NO MISO arm received a further 20 Gy in 2 Gy fractions (5/week). Patients in the PLUS MISO arm received a further 12 Gy in 6 Gy fractions (1/week). MISO was administered orally (3.0 g m-2) and intravesically (1.0 g in 35 ml of solvent) 4 h and 2 h respectively prior to each fraction of 6 Gy. Fifty-eight patients were randomized of whom 53 are evaluable. There is a minimum follow-up of 5 years in the surviving patients. In the NO MISO and PLUS MISO arms, the complete response rate at cystoscopy at 6 months was 63% and 69%, the 5-year survival rate was 41% and 48% and the 5-year local control rate with bladder preservation was 46% and 36% respectively (censored for death from metastases while locally clear). These differences are not statistically significant. Two patients had grade 3 RTOG late bowel complications. Both patients were in the PLUS MISO arm, had undergone salvage cystectomy and subsequently required colostomies for bowel obstruction for a 5-year late complication rate (RTOG grade 3) of 9%. In addition, two patients in the PLUS MISO arm developed wound sepsis post cystectomy. We were not able to demonstrate improved results from the use of oral and intravesical MISO in this study. The number of patients entered are relatively low and large differences would have been required to be detected with a power of 0.80. The use of an unconventional radiation fractionation schedule may have resulted in increased bowel morbidity in patients in the PLUS MISO arm who subsequently underwent cystectomy.

Full text

PDF
968

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abratt R. P. A new approach to the use of misonidazole as a radiosensitizer of hypoxic tumour cells. Br J Cancer. 1982 Dec;46(6):976–979. doi: 10.1038/bjc.1982.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Abratt R. P., Barnes D. R., Pontin A. R., Sarembock L. A., Williams A. M. Radical radiation and oral and intra-vesical misonidazole for bladder cancer. Int J Radiat Oncol Biol Phys. 1987 Jul;13(7):1053–1055. doi: 10.1016/0360-3016(87)90044-7. [DOI] [PubMed] [Google Scholar]
  3. Abratt R. P., Sealy R., Tucker R. D., Williams M. A., Barnes D. R., Johnson M. B., Green J. A., Cridland J. S. Radical irradiation and misonidazole in the treatment of T2 grade III and T3 bladder cancer. Int J Radiat Oncol Biol Phys. 1983 May;9(5):629–632. doi: 10.1016/0360-3016(83)90227-4. [DOI] [PubMed] [Google Scholar]
  4. Adams G. E. Hypoxic cell sensitizers for radiotherapy. Int J Radiat Oncol Biol Phys. 1978 Jan-Feb;4(1-2):135–141. doi: 10.1016/0360-3016(78)90129-3. [DOI] [PubMed] [Google Scholar]
  5. Asquith J. C., Watts M. E., Patel K., Smithen C. E., Adams G. E. Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles. Radiat Res. 1974 Oct;60(1):108–118. [PubMed] [Google Scholar]
  6. Awwad H. K., Abd El Moneim H., Abd El Baki H., Omar S., El Merzabani M., Farag H. I. The topical use of misonidazole in bladder cancer. Prog Clin Biol Res. 1983;132D:305–316. [PubMed] [Google Scholar]
  7. Dische S., Saunders M. I., Flockhart I. R., Lee M. E., Anderson P. Misonidazole-a drug for trial in radiotherapy and oncology. Int J Radiat Oncol Biol Phys. 1979 Jun;5(6):851–860. doi: 10.1016/0360-3016(79)90070-1. [DOI] [PubMed] [Google Scholar]
  8. Fathi M. A., Fisher G. J., Pageau R., Tahan T. W., Nigam V. N., Brailovsky C. A., Elhilali M. M. Systemic, bladder wall, and bladder tumor concentration of misonidazole following intravesical administration in the rat. Int J Radiat Oncol Biol Phys. 1983 Sep;9(9):1397–1400. doi: 10.1016/0360-3016(83)90273-0. [DOI] [PubMed] [Google Scholar]
  9. Fowler J. F., Sheldon P. W., Denekamp J., Field S. B. Optimum fractionation of the C3H mouse mammary carcinoma using x-rays, the hypoxic-cell radiosensitizer Ro-07-0582, or fast neutrons. Int J Radiat Oncol Biol Phys. 1976 Jul-Aug;1(7-8):579–592. doi: 10.1016/0360-3016(76)90139-5. [DOI] [PubMed] [Google Scholar]
  10. Fowler J. F. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989 Aug;62(740):679–694. doi: 10.1259/0007-1285-62-740-679. [DOI] [PubMed] [Google Scholar]
  11. Papavasiliou C., Yiogarakis D., Davillas N., Seretakis L., Pappas J., Licourinas M., Theodorou C., Stathopoulos P., Katsoyianni C., Thanos A. Treatment of bladder carcinoma with irradiation combined with misonidazole. Int J Radiat Oncol Biol Phys. 1983 Nov;9(11):1631–1633. doi: 10.1016/0360-3016(83)90415-7. [DOI] [PubMed] [Google Scholar]
  12. Sheldon P. W., Fowler J. F. Radiosensitization by misonidazole (Ro-07-0582) of fractionated X-rays in a murine tumour. Br J Cancer Suppl. 1978 Jun;3:242–245. [PMC free article] [PubMed] [Google Scholar]
  13. Shipley W. U., Rose M. A., Perrone T. L., Mannix C. M., Heney N. M., Prout G. R., Jr Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J Urol. 1985 Oct;134(4):679–683. doi: 10.1016/s0022-5347(17)47381-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES